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Abstract: Over the past decades, a number of phytochemicals have been reported to possess 
potent pharmacological effects. Saikosaponins represent a group of oleanane derivatives, 
usually as glucosides, which are common found in medicinal plants Bupleurum spp., which 
have been used as traditional Chinese medicine for more than 1,000 years in China. Emerging 
evidence suggests that saikosaponins have many pharmacological effects, including sedation, 
anticonvulsants, antipyretic, antiviral, immunity, anti-inflammation, antitumor, protecting 
liver and kidney and so on. The present review provides a comprehensive summary and 
analysis of the pharmacological properties of saikosaponins, supporting the potential uses of 
saikosaponins as a medicinal agent. 
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1. Introduction 
The root of Bupleurum chinensis DC., a well-known medicinal plant in China, was 
originally documented in the “Shennong's Herbal”, which is the oldest Chinese materia 
medica monographs. Radix Bupleuri is perennial herbaceous plants of Umbelliferae, and its 
action is regulating the function relation of internal organs to relieve fever, disperse the 
stagnation of liver-qi and uplift yang-qi to raise sinking in the traditional Chinese medicine 
(TCM) theory. Therefore, the TCM clinic is used for fever due to exogenous pathogenic 
factors with alternating episodes of chills and fever. And it is effective in eliminating the 
pathogenic factors located in the half-superficial and half-interior, hence it is an indispensable 
medicine for treating shaoyang disease, which is manifested as feeling of fullness and 
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oppression in the chest and hypochondrium, bitter taste in the mouth and dry throat, and 
relieving constraint for improving symptoms of emotionalin stability such as depression, 
anxiety and phobia. However, in recent 10 years, 43 kinds of saponins have been separated 
and identificated, and according to their differences of chemical structures bupleurum 
saponins can be divided into -a, -b, -c , -d, -m, -n, -p and -t, while saikosaponin d (SSd) is 
believed to be the most active among them, and saikosaponin a (SSa) is the second most 
active [1]. For the most part, saponins are extracted from bupleurum root, while saponins 
derived from the ground part are rare [2]. Saikosaponins (SS) are major biological active 
ingredients in R. bupleuri. Saikosaponins represent a group of oleanane derivatives, usually as 
glucosides, that are found in a number of plant families. Saikosaponins isolated from 
medicinal plants such as Bupleurum spp., Heteromorpha spp. and Scrophularia scorodonia 
have been reported to possess various biological activities, namely antihepatitis, antinephritis, 
antihepatoma, anti-inﬂammation and antibacterial effects, as well as being able to modulate 
immune function. Saikosaponins (a, b, c, and d) have been reported to have sedative and 
analgesic, anti-inflammatory, antibacterial, protect liver, kidney, anticancer, antivirus and 
other pharmacological effects. With regard to the latest use of saikosaponins (A, B, C and D) 
(Figure 1), we have summarized in Tables 1, 2, 3 and 4. In addition, the pharmacodynamic 
effect and mechanism of saikosaponins have the new research progress in the world and all 
literatures available are reviewed. 
2. Pharmacology 
2.1Central neverous systerm 
2.1.1 Antiepileptic activity 
Epilepsy is one of the most common neurological disorders, yet its treatment remains 
unsatisfactory. SSa, a triterpene saponin derived from B. chinensis DC., has been 
demonstrated to have significant antiepileptic activity in a variety of epilepsy models in vivo. 
Research found that SSa effectively terminated spontaneous recurrent epileptiform discharges 
(SREDs) in the HNC model of AE and continuous epileptiform high-frequency bursts (SE) in 
the hippocampal neuronal culture (HNC) model of SE, in a concentration-dependent manner 
with an IC50 of 0.42 mM and 0.62 mM, respectively [3]. 
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By observing the electroencephalogram (EEG) of epileptic rats, the therapeutic effects of 
saikosaponins on epilepsy can be evaluated. Sixty 8-week-old healthy SD rats were 
randomized into normal control group, epileptic model group, lamotrigine group, and 3 
saikosaponin groups of small, moderate and high doses, with 10 rats in each group. Penicillin 
was used to induce epilepsy in the latter 5 groups, and the EEG and onset of epileptic seizures 
were observed in each group. Result showed that saikosaponins can obviously alleviate the 
severity of epileptic seizure in epileptic rats [4]. Neonatal rat hippocampal astrocytes could be 
treated with SSa. SSa resulted in significant inhibition of cell proliferation, cell division and 
GFAP expression in the Glu-activated astrocytes. Glu-induced activation of rat hippocampal 
astrocytes can be inhibited by SSa, whose antiepileptic effect is probably mediated by 
inhibition of hippocampal astrocyte activation [5]. 
Acute epileptic seizure was induced by pentylenetetrazole (PTZ) in rats, and the seizure 
incubation period and the number of rats with tetanic convulsion were recorded to study the 
antiepileptic effect of SSa. After treatment with SSa, the incubation period of PTZ-induced 
seizure was significantly prolonged (P<0.01), and the rate of tetanic convulsion was 
significantly reduced (P<0.05). And SSa can inhibit epileptic seizure induced by PTZ [6,7]. 
Forty-eight healthy Sprague-Dawley rats were randomly divided into 6 equal groups, and 
except those in the blank control group, the rats in the other groups were all given different 
treatments to induce kindling by intraperitoneal injection of PTZ on a daily basis for 4 
consecutive weeks. Seizure frequency in the 3 saikosaponins groups decreased 2 weeks later, 
which was especially obvious in the high-dose group (P<0.05). The kindling rate was 
significantly lower in high-dose saikosaponins group than in the other treatment groups after 
4 weeks of the treatment (P<0.05), with also less intense seizure onset (P<0.01) and 
differences in the wave form of EEG [8]. 
2.1.2 Antidepressant activity 
Pretreatment of PC12 cells with total saikosaponins (TSS) (3.125, 6.25, 12.5, 25 μg/mL) 
partly reversed corticosterone-induced neurotoxicity in a dose dependent manner. TSS (25 
μg/mL) reversed the increase of dead cells in the hoechst stain, the accumulation in LDH 
leakage and the number of TUNEL positive cells induced by corticosterone to PC12 cells. 
Moreover, the cytoprotection of TSS was proved to be associated with the homeostasis of in 
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tracellular Ca²+, the stabilization of ER stress via the down-regulation of GRP78, GADD-153, 
XBP-1, and the restoration of mitochondrial function, which included mPTP, MMP and 
caspase-3 activity. The result indicated that the antidepressant-like effect of TSS in vivo may 
be associated with the cytoprotection of neuron, and the neuroprotective mechanisms were 
co-related with inhibiting the ER stress and the mitochondrial apoptotic pathways [7].  
2.2 Neuropathic pain 
 Neuropathic pain was induced by chronic constriction injury (CCI) of the sciatic nerve 
in rats. After CCI, rats were administered SSa (6.25, 12.50 and 25.00 mg/kg intraperitoneal, 
once daily) for 14 days. Mechanical withdrawal threshold and thermal withdrawal latency 
were assessed before surgery and on days 1, 3, 7, and 14 after CCI. Our results showed that 
CCI significantly decreased mechanical withdrawal threshold and thermal withdrawal latency 
on days 1, 3, 7 and 14, as compared with sham groups, however, SSa reversed this effects. In 
addition, SSa can inhibit the levels of TNF-α, IL-1β, IL-2 in rat spinal cord by CCI-induced. 
Western blot analysis demonstrated that saikosaponin a reduced the elevated expression of 
p-p38 mitogen-activated protein kinase (MAPK) and NF-κB in the spinal cord induced by 
CCI. These results suggest that saikosaponin a could effectively attenuate neuropathic pain in 
CCI rats by inhibiting the activation of p38 MAPK and NF-κB signaling pathways in spinal 
cord [9]. 
2.3 Anticancer activity 
The effects of saikosaponins (a, b1, b2, c, d) on the induction of differentiation in rat C6 
glioma cells were studied. SSa and d were shown to inhibit cell proliferation and alter cell 
morphology, and the results suggest that SSa can induce the differentiation of C6 glioma cells 
into astrocytes and/or oligodendrocytes, but SSd can only induce the differentiation of C6 
glioma cells into astrocytes [10]. And SSd could inhibit the activated T lymphocytes via 
suppression of NF-κB, NF-AT and AP-1 signaling. Here, SSd significantly potentiated 
TNF-ß-mediated cell death in HeLa and HepG2 cancer cells via suppression of TNF-ß 
induced NF-κB activation and its target genes expression involving cancer cell proliferation, 
invasion, angiogenesis and survival. Also, SSd revealed a significant potency of abolishing 
TNF-ß induced cancer cell invasion and angiogenesis in HUVECs while inducing apoptosis 
via enhancing the loss of mitochondrial membrane potential in HeLa cells. These findings 
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indicate that SSd has a significant potential to be developed as a combined adjuvant remedy 
with TNF-ß for cancer patients [11]. SSd inhibits the cell growth of human lung cancer cell 
line A549 and provides a molecular understanding of this effect. It was showed that SSd 
inhibited the proliferation of A549 by inducing apoptosis and blocking cell cycle progression 
in the G1 phase [12]. To observe the effect of SSd on reversing the malignant phenotype of 
HepG2 cells and to investigate its mechanism in order to prove that SSd is a new choice to 
prevent and treat HCC. HepG2 cells were cultured and treated by different concentration of 
SSd demonstrating that SSd could reverse the malignant phenotype of HepG2 cells, and 
hinting SSd can be a new choice to prevent and treat HCC [13]. In vitro, MTT assay showed 
that SSd treatment inhibited cell proliferation in three human anaplastic thyroid cancer cell 
lines ARO, 8305C and SW1736. And SSd promoted cell apoptosis and induced G1-phase cell 
cycle arrest as shown by flow cytometric analysis. The research study suggested that SSd 
might be a new potent chemopreventive drug candidate for human undifferentiated thyroid 
carcinoma through induction of apoptosis and cell cycle arrest [14]. Used transmission 
electron microscopy (TEM) to observe ultrastructural changes of cells found the combination 
of SSd and radiotherapy had a time-dependent synergistic effect. Radiation caused 
ultrastructural damage to cells, and the damage was enhanced in combination with SSd. 
Radiation decreased the GSH content and increased the MDA content in cells, and this effect 
was suppressed after the intervention of SSd. SSd can inhibit the growth of SMMC-7721 
hepatoma cell lines in vitro. Additionally, it significantly enhances the effects of radiation on 
inhibiting the growth of SMMC-7721 hepatoma cell lines, and up-regulates the antioxidant 
level after the radiotherapy [15]. Research showed that treatment with SSd inhibited DU145 
cell proliferation in a concentration-dependent manner. Flow cytometric analysis showed that 
SSd inhibited the proliferation of DU145 cells by induction of apoptosis and cell cycle arrest 
at G0/G1 phase. Further mechanistic experiments demonstrated that SSd arrested the cell 
cycle at G0/G1 phase via upregulation of p53 and p21 and induced apoptosis by modulating 
B-cell lymphoma 2 family proteins, dissipation of the mitochondrial membrane potential, 
release of cytochrome c into the cytosol and activation of caspase-3. 
2.4 Anti-liver cancer and the potential hepatotoxicity 
Treatment with SSd decreased the cell proliferation of Hep G2 and Hep 3B cells in a 
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dose dependent manner. SSd blocked the progression of cell cycle at G1 phase by inducing 
p53 expression and further up-regulating p21/WAF1 expression. Furthermore, SSd also 
inhibited the cell survival signaling by enhancing the amount of IkBa in cytoplasm and 
reducing the level and activity of NF-κB in the nucleus, and subsequently attenuated the 
expression of Bcl-XL in Hep G2 and Hep 3B cells. SSd decreased the cell proliferation and 
induced apoptosis both in p53-postive Hep G2 and p53-negative Hep 3B cell. Male SD rats 
were divided into control, model and SSd groups, and model and SSd groups given 
intragastric 0.2% (w/v) N-diethylnitrosamine to induce HCC. SSd group received 0.03% (w/v) 
SSd in saline. Liver samples were analysed immunohistochemically for syndecan-2, MMP-2, 
MMP-13 and TIMP-2 at 16 weeks. The model group had more malignant nodules than the 
SSd group, and SSd inhibited HCC development, and down-regulated expressions of 
syndecan-2, MMP-2, MMP-13 and TIMP-2 in rat HCC liver tissue [16]. An experimental 
model with diethylinitrosamine (DEN)-treated Sprague Dawley rats was used in the present 
study. The liver nodule formation, tumorous invasion to surrounding organs and increased 
cellular atypia induced by DEN were markedly reduced by SSd in the SSd + DEN group 
compared with the DEN group. This results suggest that SSd prevents DEN-induced 
hepatocarcinogenesis in rats through inhibition of C/EBPβ and COX-2 [17]. 
The proliferation and migration of hepatic stellate cells (HSCs) profoundly impact the 
pathogenesis of liver inflammation and fibrogenesis. SSa and SSd are the major active 
components of triterpene saponins in Bupleurum falcatum. Experimental results indicate that, 
in addition to suppressing HSC-T6 proliferation, wound healing activity and cell migration in 
a time- and dose-dependent manner, SSa and SSd significantly induce apoptosis. Additionally, 
SSa and SSd decreased the expressions of extracellular matrix-regulated kinase 1/2 (ERK1/2), 
platelet-derived growth factor receptor 1 (PDGFR1), and subsequently transformed growth 
factor-β1 receptor (TGF-β1R), α-smooth muscle actin, TGF-β1 and connective tissue growth 
factor. They also decreased phosphorylation of p38 (p-p38) and ERK1/2 (p-ERK1/2) of 
HSC-T6. Furthermore, both SSa and SSd can block PDGF-BB and TGF-β1-induced cell 
proliferation and migration of HSC-T6 [18]. Hepatic fibrosis model rats that were induced by 
subcutaneous injection of CCl4 were injected intraperitoneally with SSd at different doses (1.0, 
1.5 and 2.0 mg/kg). The results demonstrated that SSd could attenuate the area and extent of 
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necrosis and reduce the scores of liver fibrosis [19,20]. A rat model of liver fibrosis was 
established using the dimethylnitrosamine. Liver tissue and serum were used to examine the 
effect of SSd on liver fibrosis. A hepatocyte culture was also used to investigate how SSd can 
protect hepatocytes from oxidative injury induced by carbon tetrachloride. The results showed 
that SSd significantly reduced collagen I deposition in the liver and alanine aminotransferase 
level in the serum. SSd was able to alleviate hepatocyte injury from oxidative stress. In 
conclusion, SSd could postpone the development of liver fibrosis by attenuating hepatocyte 
injury [21]. 
However, recent investigations and clinical practice have indicated that this medicinal 
herb has potential hepatotoxicity, questioning the clinical safety of using it [22]. 
Saikosaponins have been identiﬁed to be the primary bioactive components contained in B. 
falcatum, and many saikosaponins have been isolated from this plant, but SSd is believed to 
be the most active among them [23]. Therefore, SSd is highly possible to act as the major 
culprit responsible for hepatotoxicity. And its trongly strengthened the research that SSd 
inhibited cell proliferation and induced mitochondrial apoptosis in human hepatocyte LO2 
cells. This pro-apoptotic effect could be attributed to SSd interruption of PDGF-bR/p38 
cascade. And these data offered mechanistic insights into the potential hepatotoxicity of 
saikosaponins as well as relevant herbal prescriptions. 
2.5 Immunomodulatory activity 
Saikosaponin has a very significant role in the protection of radiation in mice and 
enhancement of the immune effects. Experiments showed that the extracts of South and North 
Bupleurum were significantly enhanced lymphocyte proliferation, interleukin-2 and tumor 
necrosis factor secretion levels . 
Research found that SSd can inhibit T cell activation through the suppression of CD69 
and CD71 expressions and IL-2 production, and the modulation of PKC pathway through 
PKCh, JNK, and NF-κB transcription factor. This may candidate for use in the treatment of 
inflammatory and autoimmune diseases including SLE. The effects of SSd on activated 
mouse T lymphocytes through the NF-κB, NF-AT and AP-1 signaling pathways, cytokine 
secretion, and IL-2 receptor expression have been investigated [24]. The results demonstrated 
that SSd not only suppressed OKT3/CD28-costimulated human T cell proliferation, it also 
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inhibited PMA, PMA/Ionomycin and Con A-induced mouse T cell activation in vitro. These 
results indicate that the NF-κB, NF-AT and AP-1 (c-Fos) signaling pathways are involved in 
the T cell inhibition evoked by SSd, so it can be a potential candidate for further study in 
treating T cell-mediated autoimmune conditions [1]. The effects of SSd on the signaling 
pathways of T cell activation were examined. The results showed that SSd potently 
suppressed both early (CD69) and late (CD71) expressions of mouse T cells stimulated with 
Con A or PMA. It interfered with PKCh translocation from cytosol to membrane fraction and 
inhibited the phosphorylations of IjBa and JNK in PMA-activated mouse T cells. Additionally, 
it inhibited PMA and ionomycin-stimulated IL-2 production in mouse T cells. These results 
indicate that the mechanism by which SSd inhibits T cell activation would involve the 
suppression of CD69 and CD71 expressions and IL-2 production, and the modulation of PKC 
pathway through PKCh, JNK, and NF-κB transcription factor. This may herald a novel 
approach for further studies of SSd as a candidate for use in the treatment of inflammatory 
and autoimmune diseases [24]. The aim of the present study was to investigate the effect of 
SSd on the differentiation, maturation and function of human monocyte-derived dendritic 
cells (DCs) isolated from condylomata acuminate patients. The results of the present study 
demonstrated that SSd reduced the differentiation of DCs, as evidenced by decreased 
expression levels of cluster of differentiation (CD)1a, CD80 and CD86 molecules and 
increased CD14 expression. Expression levels of the mannose receptor and CD32 were also 
significantly elevated, which was associated with enhanced fluorescein isothiocyanate-dextran 
endocytic activity. Furthermore, SSd treatment promoted DC maturation by increasing the 
expression levels of CD40, CD83, CD80 and CD86. In addition, the function of mature DCs, 
including the secretion of IL-12 and the stimulation of lymphocyte proliferation, was 
significantly increased following SSd administration. In conclusion, the present study 
indicated that SSd exhibited immunomodulatory effects and may be a novel potent 
chemopreventive drug candidate for the treatment of condylomata acuminate [25]. 
2.6 Anti-inflammatory activity 
Bupleurum saponins exhibit multiple pharmacological activities including 
anti-inflammatory and anti-cancer effects. Moreover, SSd has been reported to attenuate 
toxin-induced hepatocyte injury and hepatic fibrosis in animal models through the inhibition 
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of several types of inflammatory mediators. Buddlejasaponin I and saikosaponins 1 and 2, 
biologically active compounds from S. scorodonia and Bupleurum rigidum respectively, exert 
potent in vivo antiinflammatory effects on mouse ear edema induced by phorbolmyristate 
acetate (PMA). The effects of these compounds on swelling and other inflammatory 
parameters are described. The effects of saikosaponins on cellular systems generating 
cyclooxygenase (COX) and lipoxygenase (LOX) metabolites were also evaluated in vitro [26]. 
SSa and SSd exhibited significant anti-inflammatory activity in two different murine models 
of acute inflammation, carrageenan-induced paw edema in rats and acetic acid-induced 
vascular permeability in mice. SSa and SSd showed potent anti-inflammatory activity through 
inhibitory effects on NF-κB activation and thereby on iNOS, COX-2 and pro-inflammatory 
cytokines [27]. Current study examines the effects of SSd on progression of 
mesangioproliferative glomerulonephritis induced by anti-Thy1 monoclonal antibody 1-22-3 
(mAb 1-22-3) in uninephrectomized rats. SSd inhibits the progression of 
mesangioproliferative glomerulonephritis through reduction of the expression of TGF-beta 1 
and the infiltration of macrophages and CD8+ T lymphocytes [28]. Chorioallantoic membrane 
(CAM) model was established successfully in chicken embryos. They were divided into SSd 
treated groups and the control group treated with PBS. Microscopic examinations showed that 
the number of microvessels and infiltrated inflammatory cells in the sponge and peripheral 
CAM mesenchyme in the SSd groups were less than those in the control group, especially on 
vessels of medium and small size (P < 0.05, P < 0.01, respectively), but was insignificant on 
great vessels (P > 0.05). SSd could inhibit the physiological angiogenesis of chicken embryoe, 
especially for the medium and small vessels, while there was no significant effect on great 
vessels (P > 0.05). Its mechanism of action may be related to its inhibition on leukocyte 
migration and activation [29]. Three saikosaponins were isolated from the MeOH extract of 
the roots of B. falcatum L.: saikosaponins B3 (1); B4 (2); and D (3). Of the three, compound 3 
inhibited the interaction of selectins (E, L, and P) and THP-1 cells with IC50 values of 1.8, 3.0 
and 4.3 µM, respectively. Also, the aglycone structure of compound 3 showed moderate 
inhibitory activity on L-selectin-mediated cell adhesion. From these results, researchers 
suspect that compound 3 isolated from B. falcatum roots would be a good candidate for 
therapeutic strategies to treat inflammation [30]. C57/BL6 mice were administered SSd 
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intraperitoneally once daily for 5 days, followed by APAP challenge. Biochemical and 
pathological analysis revealed that mice treated with SSd were protected against 
APAP-induced hepatotoxicity. SSd markedly suppressed phosphorylation of nuclear factor 
kappa B (NF-κB) and signal transducer and activator of transcription 3 (STAT3) and reversed 
the APAP-induced increases in the target genes of NF-κB, such as pro-inflammatory cytokine 
Il6 and Ccl2, and those of STAT3, such as Socs3, Fga, Fgb and Fgg. SSd also enhanced the 
expression of the anti-inflammatory cytokine Il10 mRNA. Collectively, these results 
demonstrate that SSd protects mice from APAP-induced hepatotoxicity mainly through 
down-regulating NF-κB and STAT3-mediated inflammatory signaling. This study unveils one 
of the possible mechanisms of hepatoprotection caused by B. falcatum and/or SSd. Bacterial 
lipopolysaccharide (LPS) is an important mediator of inflammation and a potent inducer of 
endothelial cell damage and apoptosis. LPS triggered caspase-3 activation, which was found 
to be important in LPS-induced HUVEC apoptosis. Inhibition of caspase-3 also inhibited 
LPS-induced degradation of focal adhesion kinase (FAK), indicating that caspase-3 is 
important in LPS-mediated FAK degradation as well as in apoptosis in HUVECs. SSc 
significantly inhibited LPS-induced apoptotic cell death in HUVECs through the selective 
suppression of caspase-3. SSc was also shown to rescue LPS-induced FAK degradation and 
other cell adhesion signals. Furthermore, the protective effects of SSc against LPS-induced 
apoptosis were abolished upon pretreatment with a FAK inhibitor, highlighting the 
importance of FAK in SSc activity. Taken together, these results show that SSc efficiently 
inhibited LPS-induced apoptotic cell death via inhibition of caspase-3 activation and 
caspase-3-mediated-FAK degradation. Therefore, SSc represents a promising therapeutic 
candidate for the treatment of vascular endothelial cell injury and cellular dysfunction [31]. 
2.7 Antiviral activity 
Saikosaponins represent a group of oleanane derivatives, usually as glucosides, that are 
found in a number of plant families, and saikosaponins (a, b2, c and d) have been shown to be 
active against human immunodeficiency virus (HIV), measles, influenza virus, herpes 
simplex virus 14 and varicellazoster virus [32]. In an attempt to find new anti-HCoV 
compounds, researcher conducted a series of experiments to investigate the antiviral activity 
and mode of action of saikosaponins against HCoV-229E in vitro. In the present study, 
 12 
 
saikosaponin b2 (SSb2) was found to: (i) inhibit HCoV-229E viral infection at concentrations 
of 25 mmol/L or less; (ii) inhibit viral attachment to cells in a dose-dependent manner; (iii) 
block viral penetration into cells; and (iv) interfere with the early stage of viral replication, 
such as virus absorption and penetration [32-39]. In the time-of-addition studies, SSb2, at 6 
mmol/L, significantly inhibited human coronavirus 229E infection following its addition at 
various time pre-infection (-4 to -1 h), coinfection (0 h) and post-infection (1–4 h). 
Furthermore, SSb2 also showed an inhibitory effect on viral attachment and penetration [32]. 
Infectious HCV culture systems were used to examine the effect of saikosaponins on the 
complete virus life cycle (entry, RNA replication/translation, and particle production). SSb2 
inhibited infection by several genotypic strains and prevented binding of serum-derived HCV 
onto hepatoma cells. Finally, treatment with the compound blocked HCV infection of primary 
human hepatocytes. SSb2 may be of value for development as an antagonist of HCV entry and 
could be explored as prophylactic treatment during the course of liver transplantation [40]. 
 
3. Discussion 
Bupleurum saponins are the main effective components of R. Bupleuri, which is reported 
to have various biological and pharmacological properties. Their important biological 
activities have attracted broad interests from both natural products chemists and 
pharmacologist over the last half century. At present, the deep research on therapeutic effects 
of single Bupleurum saponins, especially in the aspects of metabolic regulation, which has 
become a focus research, such as, receptor of ion channels and the effect of many links of 
signal transduction pathway, and so on. However, the research of Bupleurum saponins in 
composition and dosage on the compatibility was still insufficient, and it needs to be 
strengthened in future. In addition, the development of the SS medicinal effective still has a 
lot of work to do, such as, the technology of separation and extraction is improved, in order to 
get more active ingredients. The focus of future work should be on the discovery of more 
active Bupleurum saponins, and the clinical application of these compounds. 
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Table 1.The pharmacologic activity of SSa. 
Tissue or cell type Observation Activity Mechanism of action Refs: 
Rat C6 Glimo Cells In vitro Atiproliferation and alerting 
morphology of cell     
Induce the differentiation of C6 glioma cellsinto astrocytes [10] 
RAW264.7cells In vitro and In 
vivo 
Anti-inflammatory activity Inhibitory effects on NF-κB activation [26] 
RAW 264.7 cells In vitro Anti-inflammatory activity response Inhibiting the MAPK and NF-κB pathways in 
LPS-stimulated RAW 264.7 cells 
[41] 
Liver (LX-2cells) In vitro Treatment of liver disease Elevated BMP-4 expression [42] 
Rat mast cell In vitro Inhibitory activity against allergic 
asthma 
Antagonism of the histamine action and inhibition of 
allergic mediators 
[43] 
Neuronal system (Hippocampal 
Neuronal) 
In vitro Anticonvulsant Inhibitions of NMDA receptor current and INaP [3] 
Neuronal system In vivo Attenuate cocaine-reinforced behavior Activation of GABAB receptors [44] 
Neuronal system In vivo Anticonvulsant Inhibits epileptiform discharges induced by 4AP [45] 
Liver In vivo Protects against CCL4-induced liver 
injury 
Attenuating hepatic lipids and lipid peroxidation [46] 
Hippocampal astrocytes In vivo  Hippocampal astrocytes can be 
inhibited 
Inhibition of hippocampal astrocyte activation [47] 
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Table 2.The pharmacologic activity of SSb. 
Tissue or cell type Observation Activity   Mechanism of action Refs 
Rat C6 Glimo Cells In vitro Anti-proliferation and alerting   
morphology of cell     
Induce the differentiation of C6 glioma cells into 
astrocytes 
[10] 
RAW264.7 cells In vitro and In vivo Anti-inflammatory activity Inhibitory effects on NF-κB activation [26] 
Liver (hepatocyte) In vivo Inhibiting hepatic fibrosis Down-regulation of liver TNF-α, IL-6 and NF-κB, 
p65 expression and the increased I-κBα activity in 
liver. 
[20] 
Lymphocytes In vitro Induction of apoptosis Increases in c-myc and p53 mRNA levels [48] 
Liver (hepatocellular 
carcinoma cells) 
In vitro Increases the radio sensitivity of 
smmc-7721 hepatocellular carcinoma 
Adjusting the g0/g1 and g2/m checkpoints of the 
cell cycle 
[49] 
T cell In vitro Inhibition of T cell activation Modulation of PKCh, JNK, and NF-κB 
transcription factor 
[24] 
Rat HCC liver tissue. 
(hepatocellular 
carcinoma(CC)) 
In vivo Inhibition of HCC development 
 
Down regulated expression of syndecan-2, 
MMP-2, MMP-13 and TIMP-2. 
[50] 
Liver (human hepatoma 
cell) 
In vitro Induction of apoptosis and cell cycle 
arrest 
Decreased the cell proliferation and inducted 
apoptosis both in p53-postive, Hep G2 and 
p53-negative Hep 3B cells. 
[51] 
Rat hypothalamus In vivo Stimulates both CRF gene expression 
and CRF release 
Not investigated [52] 
Liver In vivo Increasion radio sensitivity of hepatoma 
cells 
Induced the upregulation of p53 and Bax as well as 
the down regulation of Bcl-2 by attenuating 
HIF-1α expression 
[53] 
Rat basophilic 
leukemia-2H3 cell 
In vitro Anti-allergic activity Inhibiting rat basophilic leukemia-2H3 cell 
degranulation by suppressing these critical 
incidents in the signal transduction pathway 
[54] 
T cell In vivo Treating T cell-mediated autoimmune Involved NF-kB, NF-AT and AP-1 (c-Fos) [1] 
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conditions signaling pathways in the T cell inhibition 
T lymphocytes In vivo Anticancer Inhibit the activated T lymphocytes via 
suppression of NF-𝜅B, NF-AT and AP-1 signaling 
[11] 
Human leukemia cells In vivo Anticancer Up-regulating GR mRNA expression and 
inhibiting cell growth 
[55] 
Chicken embryoe In vivo Inhibition of the physiological 
angiogenesis of chicken embryoe 
Inhibition on leukocyte migration and activation. 
 
[29] 
Pulmonary fibrosis In vivo Anti-fibrosis Anti-lipid peroxidation effect [56] 
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Table 3.The pharmacologic activity of SSc 
Tissue or cell type Observation Activity   Mechanism of action  Refs:   
HUVECs  In vitro  Inhibiting lipopolysaccharide-induced 
apoptosis  
 
Suppressing caspase-3 activation and subsequent 
degradation of focal adhesion kinase in human 
umbilical vein endothelial cells 
[57] 
Human umbilical vein 
endothelial cells. 
 
In vitro Treatment of vascular endothelial cell 
injury and cellular dysfunction. 
Inhibiting LPS-induced apoptotic cell death via 
inhibition of caspase-3 activation and 
caspase-3-mediated-FAK degradation 
[31] 
Lung (human non-small cell lung 
cancer A549 cells) 
In vitro Inhibiting the proliferation Inducing apoptosis and blocking cell cycle 
progression in the G1 phase. 
[31] 
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Table 4.The pharmacologic activity of SSd 
Tissue or cell type Observation Activity Mechanism of action Refs:   
Melanoma cells 
 
In vitro Inducing differentiation in cultured B16 melanoma 
cells 
Down-regulation of the PKC activity [58] 
 
 Hepatoma cells In vitro Treatment with the compound blocked HCV infection 
of primary human hepatocytes. 
Inhibiting infection caused by several genotypic 
strains and preventing the binding of serum-derived 
HCV onto hepatoma cells 
[40] 
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 Figure 1. Structures of saikosaponins (A, B, C and D) 
 
 
 
 
 
 
 
